

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Canceled)
2. (Currently Amended) An antisense oligonucleotide directed against vascular endothelial growth factor (VEGF) ~~wherein said antisense oligonucleotide inhibits proliferation of cultured Kaposi's sarcoma cells, cultured at an IC<sub>50</sub> concentration of less than or equal to about 1.5 micromolar, and~~ wherein said antisense oligonucleotide comprises a plurality of phosphorothioate moieties and has a sequence is selected from the group consisting of among SEQ ID NOS: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 28 and 29.
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Currently Amended) The ~~composition~~ antisense oligonucleotide of Claim 2 wherein said antisense oligonucleotide inhibits proliferation of cultured ovarian carcinoma cells at an IC<sub>50</sub> concentration of less than or equal to about 2 micromolar.
10. (Currently Amended) The ~~composition~~ antisense oligonucleotide of Claim 9 wherein said antisense oligonucleotide is chosen from the group consisting of SEQ ID NOS: 9, 10, 13, 14, 17, 28 and 29.

11. (Currently Amended) The ~~composition~~ antisense oligonucleotide of Claim 2 wherein said antisense oligonucleotide inhibits proliferation of cultured melanoma cells at an IC<sub>50</sub> concentration of less than or equal to about one micromolar.

12. (Currently Amended) The ~~composition~~ antisense oligonucleotide of Claim 11 wherein said antisense oligonucleotide is chosen from the group consisting of SEQ ID NOS: 12, 13, 14, and 17.

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Currently amended) A composition formulated for administration to a human, the composition comprising:

a) an antisense oligonucleotide directed against vascular endothelial growth factor (VEGF) ~~wherein said antisense oligonucleotide inhibits proliferation of cultured Kaposi's Sarcoma cells at an IC<sub>50</sub> concentration of less than or equal to about 1.5 micromolar, and wherein said oligonucleotide consists of a nucleic acid sequence which is perfectly complementary to a contiguous sequence of 19 to 33 nucleotides in the region of VEGF beginning at nucleotide 259 and ending at nucleotide 293~~ comprises a plurality of phosphorothioate moieties and has a sequence selected from the group consisting of SEQ ID NOS: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 28 and 29; and

b) a pharmacologically acceptable carrier.

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (New) The composition of Claim 16 wherein said antisense oligonucleotide is encapsulated in a liposome.

21. (New) The composition of Claim 16 further comprising an antibody that specifically interacts with a vascular endothelial growth factor or a vascular endothelial growth factor receptor.

22. (New) The composition of Claim 21 wherein said antibody is specific for Flt-1.

23. (New) The composition of Claim 21 wherein said antibody is specific for Flk-1.

24. (New) The composition of Claim 16 further comprising a second antisense oligonucleotide selected from the group consisting of SEQ ID NOS: 1-29.

25. (New) The composition of Claim 24 wherein said first and second oligonucleotides are encapsulated in a liposome.